#United States #Boston #GLP-1 #Caliway Biopharmaceuticals #CBL-514

Caliway Biopharmaceuticals to Showcase Groundbreaking CBL-514 Data at BIO 2025

Caliway Biopharmaceuticals, a clinical-stage biopharmaceutical firm, is set to participate in the 2025 BIO International Convention, held from June 16 to 19 in Boston, United States. This event, known to be the largest in the biotech industry, presents a critical opportunity for Caliway to share important advancements regarding its drug candidate CBL-514. On June 17, Caliway's Vice President April Yuan will deliver an oral presentation shedding light on the latest developments surrounding this innovative treatment, particularly in the realm of weight management.

Introduction to CBL-514

CBL-514 is a first-in-class injectable drug designed to selectively target subcutaneous fat through a process called adipocyte apoptosis. This method effectively reduces fat in designated areas while ensuring minimal systemic side effects on major body systems. Up until May 2025, the company has successfully completed ten clinical trials involving 520 subjects, confirming both efficacy and safety across various endpoints.

The Problem of Weight Rebound

As more patients globally begin using GLP-1 receptor agonists—a class of medications known for aiding in weight loss—issues have arisen concerning post-treatment weight regain. Studies indicate that merely 10% of patients can successfully maintain their reduced weight following the cessation of GLP-1 treatments. This weight rebound represents a pressing challenge in the healthcare community, where sustainable weight loss is essential for patient welfare and health management.

CBL-514's New Indication

At the upcoming convention, Caliway will reveal preclinical data on CBL-514's potential as a combination therapy with GLP-1 medications aimed at managing weight rebound. Preliminary findings suggest that administering CBL-514 alongside GLP-1 therapies can considerably diminish both the rate of weight regain and fat accumulation after patients withdraw from GLP-1 treatments.

Vivian Ling, CEO of Caliway, expressed commitment to addressing the unmet market needs surrounding post-weight-loss rebound. She stated, “We believe post-weight-loss weight rebound is a promising unmet market need. CBL-514 has the potential to serve as a complementary combination therapy with GLP-1 treatments.”

Future Plans

Caliway intends to submit a Phase 2 IND application for this new indication to the U.S. FDA by Q4 2025. The implications of successfully navigating this regulatory landscape could pave the way not just for weight management solutions but also enhance the aesthetic medicine portfolio Caliway hopes to develop.

Understanding CBL-514

Apart from its role in weight rebound management, CBL-514 is also being investigated for additional applications such as non-surgical fat reduction, treatment of moderate-to-severe cellulite, and Dercum's disease. These pursuits highlight the drug's versatility and the potential to address various aspects of patient care in the aesthetic field.

The company is optimistic that partnerships and collaborations stemming from BIO 2025 will bolster its efforts to bring breakthrough solutions to market, ultimately improving the lives of patients dealing with weight management challenges.

Event Details

Caliway's presentation is scheduled as follows:

• - Date: June 17, 2025
• - Time: 11:45 AM – 12:00 PM (EDT)
• - Location: Room 154, Boston Convention & Exhibition Center

As the biotech landscape continues to evolve, Caliway Biopharmaceuticals' contributions could represent significant advancements in weight management and aesthetic treatments. For more information about their ongoing projects and to stay updated on their progress, visit Caliway Biopharmaceuticals' official website.